Literature DB >> 17459420

Nitrosamines as nicotinic receptor ligands.

Hildegard M Schuller1.   

Abstract

Nitrosamines are carcinogens formed in the mammalian organism from amine precursors contained in food, beverages, cosmetics and drugs. The potent carcinogen, NNK, and the weaker carcinogen, NNN, are nitrosamines formed from nicotine. Metabolites of the nitrosamines react with DNA to form adducts responsible for genotoxic effects. We have identified NNK as a high affinity agonist for the alpha7 nicotinic acetylcholine receptor (alpha7nAChR) whereas NNN bound with high affinity to epibatidine-sensitive nAChRs. Diethylnitrosamine (DEN) bound to both receptors but with lower affinity. High levels of the alpha7nAChR were expressed in human small cell lung cancer (SCLC) cell lines and in hamster pulmonary neuroendocrine cells (PNECs), which serve as a model for the cell of origin of human SCLC. Exposure of SCLC or PNECs to NNK or nicotine increased expression of the alpha7nAChR and caused influx of Ca(2+), activation of PKC, Raf-1, ERK1/2, and c-myc, resulting in the stimulation of cell proliferation. Signaling via the alpha7nAChR was enhanced when cells were maintained in an environment of 10-15% CO(2) similar to that in the diseased lung. Hamsters with hyperoxia-induced pulmonary fibrosis developed neuroendocrine lung carcinomas similar to human SCLC when treated with NNK, DEN, or nicotine. The development of the NNK-induced tumors was prevented by green tea or theophylline. The beta-adrenergic receptor agonist, isoproterenol or theophylline blocked NNK-induced cell proliferation in vitro. NNK and nicotine-induced hyperactivity of the alpha7nAChR/RAF/ERK1/2 pathway thus appears to play a crucial role in the development of SCLC in smokers and could be targeted for cancer prevention.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17459420      PMCID: PMC1987356          DOI: 10.1016/j.lfs.2007.03.006

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  49 in total

Review 1.  Introduction: the non-neuronal cholinergic system in humans.

Authors:  Sergei A Grando; Koichiro Kawashima; Ignaz Wessler
Journal:  Life Sci       Date:  2003-03-28       Impact factor: 5.037

Review 2.  Mechanisms of smoking-related lung and pancreatic adenocarcinoma development.

Authors:  Hildegard M Schuller
Journal:  Nat Rev Cancer       Date:  2002-06       Impact factor: 60.716

3.  The nicotinic receptor antagonists abolish pathobiologic effects of tobacco-derived nitrosamines on BEP2D cells.

Authors:  Juan Arredondo; Alex I Chernyavsky; Sergei A Grando
Journal:  J Cancer Res Clin Oncol       Date:  2006-07-12       Impact factor: 4.553

4.  Interaction of tobacco-specific toxicants with the neuronal alpha(7) nicotinic acetylcholine receptor and its associated mitogenic signal transduction pathway: potential role in lung carcinogenesis and pediatric lung disorders.

Authors:  H M Schuller; B A Jull; B J Sheppard; H K Plummer
Journal:  Eur J Pharmacol       Date:  2000-03-30       Impact factor: 4.432

5.  NNK activates ERK1/2 and CREB/ATF-1 via beta-1-AR and EGFR signaling in human lung adenocarcinoma and small airway epithelial cells.

Authors:  E Laag; M Majidi; M Cekanova; T Masi; T Takahashi; H M Schuller
Journal:  Int J Cancer       Date:  2006-10-01       Impact factor: 7.396

Review 6.  Environmental and chemical carcinogenesis.

Authors:  Gerald N Wogan; Stephen S Hecht; James S Felton; Allan H Conney; Lawrence A Loeb
Journal:  Semin Cancer Biol       Date:  2004-12       Impact factor: 15.707

7.  Nicotinic receptors mediate tumorigenic action of tobacco-derived nitrosamines on immortalized oral epithelial cells.

Authors:  Juan Arredondo; Alex I Chernyavsky; Sergei A Grando
Journal:  Cancer Biol Ther       Date:  2006-05-13       Impact factor: 4.742

8.  Neuroendocrine lung carcinogenesis in hamsters is inhibited by green tea or theophylline while the development of adenocarcinomas is promoted: implications for chemoprevention in smokers.

Authors:  Hildegard M Schuller; B Porter; A Riechert; K Walker; R Schmoyer
Journal:  Lung Cancer       Date:  2004-07       Impact factor: 5.705

9.  Ultrastructural alterations of nonciliated cells after nitrosamine treatment and their significance for pulmonary carcinogenesis.

Authors:  H Reznik-Schüller
Journal:  Am J Pathol       Date:  1976-12       Impact factor: 4.307

Review 10.  Recent studies on mechanisms of bioactivation and detoxification of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific lung carcinogen.

Authors:  S S Hecht
Journal:  Crit Rev Toxicol       Date:  1996       Impact factor: 5.635

View more
  49 in total

Review 1.  The emerging role of smoking in the development of pancreatitis.

Authors:  Martine Alexandre; Stephen J Pandol; Fred S Gorelick; Edwin C Thrower
Journal:  Pancreatology       Date:  2011-10-05       Impact factor: 3.996

2.  Screening of tobacco smoke condensate for nicotinic acetylcholine receptor ligands using cellular membrane affinity chromatography columns and missing peak chromatography.

Authors:  Alexandre Maciuk; Ruin Moaddel; Jun Haginaka; Irving W Wainer
Journal:  J Pharm Biomed Anal       Date:  2007-11-26       Impact factor: 3.935

Review 3.  Is cancer triggered by altered signalling of nicotinic acetylcholine receptors?

Authors:  Hildegard M Schuller
Journal:  Nat Rev Cancer       Date:  2009-02-05       Impact factor: 60.716

Review 4.  How cigarette smoke skews immune responses to promote infection, lung disease and cancer.

Authors:  Martin R Stämpfli; Gary P Anderson
Journal:  Nat Rev Immunol       Date:  2009-05       Impact factor: 53.106

5.  The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer.

Authors:  Margaret R Spitz; Christopher I Amos; Qiong Dong; Jie Lin; Xifeng Wu
Journal:  J Natl Cancer Inst       Date:  2008-10-28       Impact factor: 13.506

6.  Tobacco nitrosamine N-nitrosonornicotine as inhibitor of neuronal nicotinic acetylcholine receptors.

Authors:  Ariane Nunes-Alves; Arthur A Nery; Henning Ulrich
Journal:  J Mol Neurosci       Date:  2012-07-31       Impact factor: 3.444

7.  Analysis of pyridyloxobutyl and pyridylhydroxybutyl DNA adducts in extrahepatic tissues of F344 rats treated chronically with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and enantiomers of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol.

Authors:  Siyi Zhang; Mingyao Wang; Peter W Villalta; Bruce R Lindgren; Pramod Upadhyaya; Yanbin Lao; Stephen S Hecht
Journal:  Chem Res Toxicol       Date:  2009-05       Impact factor: 3.739

Review 8.  Is the Canonical RAF/MEK/ERK Signaling Pathway a Therapeutic Target in SCLC?

Authors:  Sandra Cristea; Julien Sage
Journal:  J Thorac Oncol       Date:  2016-04-29       Impact factor: 15.609

9.  Prevention of pancreatic cancer by the beta-blocker propranolol.

Authors:  Hussein A Al-Wadei; Mohammed H Al-Wadei; Hildegard M Schuller
Journal:  Anticancer Drugs       Date:  2009-07       Impact factor: 2.248

10.  Quantitation of pyridylhydroxybutyl-DNA adducts in liver and lung of F-344 rats treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and enantiomers of its metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol.

Authors:  Pramod Upadhyaya; Stephen Kalscheuer; J Bradley Hochalter; Peter W Villalta; Stephen S Hecht
Journal:  Chem Res Toxicol       Date:  2008-06-21       Impact factor: 3.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.